Universal Transplants

Generation of human induced pluripotent STEM CELLS (iPSC) from haplo-selected cord blood samples

Developing HLA-homozygous hiPSC therapies, fostering collaboration, innovation, and inclusivity.

2022 - 2026

A close-up view of a cell featuring a distinct white spot on its surface, highlighting cellular structure.

COST EU

Haplo.iPS

A close-up view of a cell featuring a distinct white spot on its surface, highlighting cellular structure.

COST EU

Haplo.iPS

A close-up view of a cell featuring a distinct white spot on its surface, highlighting cellular structure.

COST EU

Haplo.iPS

HAPLO-iPS aims to create a collaborative network to provide a framework for hiPSC generation of hiPSC homozygous for frequent HLA haplotypes, compatible with a significant percentage of the population to be used for cell therapy clinical trials and to create a data collection system (REGISTRY) for such lines.